z-logo
Premium
Durability and tolerability of dapagliflozin over 52 weeks as add‐on to metformin and sulphonylurea in type 2 diabetes
Author(s) -
Matthaei S.,
Bowering K.,
Rohwedder K.,
Sugg J.,
Parikh S.,
Johnsson E.
Publication year - 2015
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12543
Subject(s) - dapagliflozin , placebo , metformin , tolerability , medicine , adverse effect , diabetes mellitus , type 2 diabetes , urology , endocrinology , gastroenterology , alternative medicine , pathology
Aims To evaluate the safety and efficacy of dapagliflozin as add‐on therapy to metformin plus sulphonylurea over 52 weeks. Methods Patients with type 2 diabetes mellitus ( T2DM ) using sulphonylurea and metformin received dapagliflozin 10 mg/day or placebo added to therapy for 52 weeks (24‐week randomized, double‐blind period plus 28‐week double‐blind extension). Results A total of 219 patients were randomized 1 : 1 to dapagliflozin or placebo. Over 52 weeks, glycated haemoglobin ( HbA1c ) and fasting plasma glucose levels showed greater improvement from baseline with dapagliflozin (−0.8% and −1.5 mmol/l) than with placebo (−0.1% and 0.6 mmol/l). More patients achieved HbA1c <7.0% with dapagliflozin (27.3%) than with placebo (11.3%) at 52 weeks. Dapagliflozin was associated with greater reductions in body weight and systolic blood pressure (−2.9 kg and −1.0 mmHg) compared with placebo (−1.0 kg and 1.1 mmHg). Greater increases in total, LDL and HDL cholesterol and decreases in triglycerides were observed with dapagliflozin (3.4, 4.8, 6.9 and −8.0%, respectively) versus placebo (1.4, 0.9, 0.6 and 2.9%, respectively). Fewer patients were rescued for failing to reach glycaemic targets with dapagliflozin (9.3%) than with placebo (44.4%). Adverse events and serious adverse events were similar between groups (dapagliflozin: 69.7 and 6.4%; placebo: 73.4 and 7.3%). More hypoglycaemic events were observed with dapagliflozin (15.6%) than with placebo (8.3%). Genital infections were reported in more patients in the dapagliflozin (10.1%) than in the placebo group (0.9%) and urinary tract infection frequency was similar in the two groups (10.1 and 11.0%). Conclusion Dapagliflozin as add‐on to metformin plus a sulphonylurea was well tolerated and improvement in glycaemic control was maintained over 52 weeks.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here